EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting mutant p53 stabilization for cancer therapy

Jiajian Wang, Wenjun Liu, Lanqing Zhang, Jihong Zhang

Frontiers in Pharmacology · 12.07.2023 · 14

DOI: 10.3389/fphar.2023.1215995 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.07.2023. Verfasst von Jiajian Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, Kunming University of Science and Technology, Kunming, China. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kunming University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over 50% cancer bears TP53 mutation, the highly stabilized mutant p53 protein drives the tumorigenesis and progression. Mutation of p53 not only cause loss-of-function and dominant-negative effects (DNE), but also results in the abnormal stability by the regulation of the ubiquitin-proteasome system and molecular chaperones that promote tumorigenesis through gain-of-function effects. The accumulation of mutant p53 is mainly regulated by molecular chaperones, including Hsp40, Hsp70, Hsp90 and other biomolecules such as TRIM21, BAG2 and Stat3. In addition, mutant p53 forms prion-like aggregates or complexes with other protein molecules and result in the accumulation of mutant p53 in tumor cells. Depleting mutant p53 has become one of the strategies to target mutant p53. This review will focus on the mechanism of mutant p53 stabilization and discuss how the strategies to manipulate these interconnected processes for cancer therapy.

Schlagwörter

Stichwörter der Autor:innen

cancerdegradationmutant p53stabilizationtarget

Autor:innen und Institutionen

  • Medical School, Kunming University of Science and Technology, Kunming, China.
  • Yunnan Province Clinical Research Center for Hematologic Disease, Kunming, China.

Förderung

  • Kunming University of Science and Technology

Zitieren

APA

Wang, J., Liu, W., Zhang, L., & Zhang, J. (2023). Targeting mutant p53 stabilization for cancer therapy. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1215995

Vancouver

Wang J, Liu W, Zhang L, Zhang J. Targeting mutant p53 stabilization for cancer therapy. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1215995

BibTeX
@article{Wang2023,
  author = {Wang, Jiajian and Liu, Wenjun and Zhang, Lanqing and Zhang, Jihong},
  title = {Targeting mutant p53 stabilization for cancer therapy},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1215995}
}
Kostenlos starten →